异基因造血干细胞移植治疗T细胞淋巴母细胞淋巴瘤——10例临床观察

[Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of T Cell Lymphoblastic Lymphoma - Clinical observation of 10 Cases].

作者信息

Gong Fang, Chen Heng, Zhao Lin-Yan, Wang Tong, Zhang Ri, Wu De-Pei

机构信息

Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China.

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Dec;24(6):1759-1763. doi: 10.7534/j.issn.1009-2137.2016.06.026.

DOI:10.7534/j.issn.1009-2137.2016.06.026

PMID:28024490

Abstract

OBJECTIVE

To analyze the result of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for treatment of patients with T cell Lymphoblastic lymphoma(T-LBL).

METHODS

The engraftment, graft versus host disease (GVHD), infection, relapse and survival of 10 T-LBL patients received allo-HSCT was observed. The clinical outcome of allo-HSCT for T-LBL patients was analyzed.

RESULTS

The median age of patients was 25 years old, 10 (6 males and 4 females) T-LBL patients received allo-HSCT including 3 from HLA-matched unrelated donors, 3 from HLA-matched sibling donors, 2 from HLA haploidentical sibling donors, and 2 from haploidentical related donors. The clinical staging showed that 1 case was in stage III and 8 cases were in stage IV. The bone marrow was involved in 7 patients. All the 10 patients achieved engraftment, and the median times of neutrophil and platelet engraftment were 11 (10-19) days and 12(7-19) days, respectively. Acute GVHD occurred in 5 patients and chronic GVHD occured in 1 patient. After the median follow-up of 26 months (11-51 months), 3 patients died, out of them 1 died from relapse after transplantation, 1 from infection and 1 from GVHD. The relapse, overall survival, and disease-free survival rate were 10%, 70%, 70%,respectively. And the estimated overall survival rate was 66.7%.

CONCLUSION

T-LBL has high rate of relapse and poor prognosis. The allo-HSCT can improve the survival of patients with T-LBL, and is an effective method for treatment of T-LBL patients.

摘要

目的

分析异基因造血干细胞移植（allo-HSCT）治疗T细胞淋巴母细胞淋巴瘤（T-LBL）患者的疗效。

方法

观察10例接受allo-HSCT的T-LBL患者的植入情况、移植物抗宿主病（GVHD）、感染、复发及生存情况。分析allo-HSCT治疗T-LBL患者的临床疗效。

结果

患者中位年龄25岁，10例（男6例，女4例）T-LBL患者接受allo-HSCT，其中3例来自HLA配型相合的无关供者，3例来自HLA配型相合的同胞供者，2例来自HLA半相合的同胞供者，2例来自半相合的亲属供者。临床分期显示，Ⅲ期1例，Ⅳ期8例。7例患者骨髓受累。10例患者均获得植入，中性粒细胞和血小板植入的中位时间分别为11（10-19）天和12（7-19）天。5例发生急性GVHD，1例发生慢性GVHD。中位随访26个月（11-51个月）后，3例患者死亡，其中1例死于移植后复发，1例死于感染，1例死于GVHD。复发率、总生存率和无病生存率分别为10%、70%、70%。估计总生存率为66.7%。